News
Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...
Douglas Adkins, MD, discusses future directions of the KEYNOTE-689 trial of pembrolizumab in head and neck cancer following the agent's FDA approval.
23h
Philstar.com on MSNWhat Filipinos need to know about head and neck cancerSmoking, alcohol consumption and betel nut chewing are some of the lifestyle factors that have been linked to head and neck ...
1d
Pharmaceutical Technology on MSNFDA approves MSD’s Keytruda to treat head and neck cancerMSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...
"After my cancer diagnosis, I knew the initial assessment had missed everything. " Courtney Liniewski told Newsweek.
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...
Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free ...
Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...
Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...
FDA has approved perioperative pembrolizumab for resectable head and neck squamous cell carcinoma, but do patients need ...
Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results